Trimodal distribution of arylamine N-acetyltransferase 1 mRNA in breast cancer tumors: association with overall survival and drug resistance

Breast cancer is one of the leading causes of cancer-related deaths in women worldwide. Unfortunately, treatments often fail because of the development of drug resistance, the underlying mechanisms of which remain unclear. Circulating tumor DNA (ctDNA) is free DNA released into the blood by necrosis, apoptosis or direct secretion by tumor cells. In contrast to repeated, highly invasive tumor biopsies, ctDNA reflects all molecular alterations of tumors dynamically and captures both spatial and temporal tumor heterogeneity. Highly sensitive technologies, including personalized digital PCR and deep sequencing, make it possible to monitor response to therapies, predict drug resistance and tailor treatment regimens by identifying the genomic alteration profile of ctDNA, thereby achieving precision medicine. This review focuses on the current status of ctDNA biology, the technologies used to detect ctDNA and the potential clinical applications of identifying drug resistance mechanisms by detecting tumor-specific genomic alterations in breast cancer.

Download Full-text

Quercetin and doxorubicin co-encapsulated biotin receptor-targeting nanoparticles for minimizing drug resistance in breast cancer

Oncotarget ◽

10.18632/oncotarget.8607 ◽

2016 ◽

Vol 7 (22) ◽

pp. 32184-32199 ◽

Cited By ~ 37

Author(s):

Li Lv ◽

Chunxia Liu ◽

Chuxiong Chen ◽

Xiaoxia Yu ◽

Guanghui Chen ◽

...

Keyword(s):

Breast Cancer ◽

Drug Resistance ◽

Receptor Targeting

Download Full-text

Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer

npj Breast Cancer ◽

10.1038/s41523-020-00208-2 ◽

2021 ◽

Vol 7 (1) ◽

Author(s):

Francesco Schettini ◽

Nuria Chic ◽

Fara Brasó-Maristany ◽

Laia Paré ◽

Tomás Pascual ◽

...

Keyword(s):

Breast Cancer ◽

Gene Expression ◽

Overall Survival ◽

High Activity ◽

Triple Negative ◽

Her2 Expression ◽

Drug Conjugates ◽

Molecular Features ◽

Biological Heterogeneity ◽

Antibody Drug

AbstractNovel antibody-drug conjugates against HER2 are showing high activity in HER2-negative breast cancer (BC) with low HER2 expression (i.e., 1+ or 2+ and lack of ERBB2 amplification). However, the clinical and molecular features of HER2-low BC are yet to be elucidated. Here, we collected retrospective clinicopathological and PAM50 data from 3,689 patients with HER2-negative disease and made the following observations. First, the proportion of HER2-low was higher in HR-positive disease (65.4%) than triple-negative BC (TNBC, 36.6%). Second, within HR-positive disease, ERBB2 and luminal-related genes were more expressed in HER2-low than HER2 0. In contrast, no gene was found differentially expressed in TNBC according to HER2 expression. Third, within HER2-low, ERBB2 levels were higher in HR-positive disease than TNBC. Fourth, HER2-low was not associated with overall survival in HR-positive disease and TNBC. Finally, the reproducibility of HER2-low among pathologists was suboptimal. This study emphasizes the large biological heterogeneity of HER2-low BC, and the need to implement reproducible and sensitive assays to measure low HER2 expression.

Download Full-text

Breast cancer preoperative 18FDG-PET, overall survival prognostic separation compared with the lymph node ratio

Breast Cancer ◽

10.1007/s12282-021-01234-z ◽

2021 ◽

Author(s):

Vincent Vinh-Hung ◽

Hendrik Everaert ◽

Olena Gorobets ◽

Hilde Van Parijs ◽

Guy Verfaillie ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Lymph Node ◽

Lymph Node Ratio ◽

18Fdg Pet ◽

Node Ratio

Download Full-text

Applicability of PD-L1 tests to tailor triple-negative breast cancer treatment in Brazil

Surgical and Experimental Pathology ◽

10.1186/s42047-021-00092-5 ◽

2021 ◽

Vol 4 (1) ◽

Author(s):

Kátia Ramos Moreira Leite ◽

Carlos Henrique Barrios ◽

Antônio Carlos Buzaid ◽

Débora Gagliato ◽

Helenice Gobbi ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Triple Negative Breast Cancer ◽

Median Overall Survival ◽

Triple Negative ◽

Breast Cancer Treatment ◽

Main Text ◽

Critical Questions ◽

Online Panel ◽

Active Interest

Abstract Background Triple-negative breast cancer (TNBC) is a heterogeneous disease that represents 10–20% of breast cancer cases. The prognosis for advanced TNBC is usually poor, with a median overall survival of approximately 18 months or less. Main text New targeted therapies such as anti-PD-L1 agents are emerging as an option to treat advanced TNBC. A panel of 6 national experts with an active interest in breast cancer convened online. Panel members had either clinical or pathology experience in breast cancer. The experts pre-defined critical questions in the management of PD-L1 in TNBC, and a literature review was performed for selected topics before the online meeting. Conclusion The experts led active discussions involving a multidisciplinary team comprising pathologists and clinical oncologists. The meeting served to discuss the most relevant issues. A total of 10 critical questions for PD-L1+ TNBC were debated and are presented in this review. This article discusses the current landscape for PD-L1 tests in TNBC in Brazil.

Download Full-text

Identification of novel cell glycolysis related gene signature predicting survival in patients with breast cancer

Scientific Reports ◽

10.1038/s41598-021-83628-9 ◽

2021 ◽

Vol 11 (1) ◽

Author(s):

Feng Jiang ◽

Chuyan Wu ◽

Ming Wang ◽

Ke Wei ◽

Jimei Wang

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Cox Regression ◽

Single Gene ◽

Prediction Method ◽

Gene Signature ◽

The Cancer Genome Atlas ◽

Cox Models ◽

Normal Tissues ◽

Predictive Risk

AbstractOne of the most frequently identified tumors and a contributing cause of death in women is breast cancer (BC). Many biomarkers associated with survival and prognosis were identified in previous studies through database mining. Nevertheless, the predictive capabilities of single-gene biomarkers are not accurate enough. Genetic signatures can be an enhanced prediction method. This research analyzed data from The Cancer Genome Atlas (TCGA) for the detection of a new genetic signature to predict BC prognosis. Profiling of mRNA expression was carried out in samples of patients with TCGA BC (n = 1222). Gene set enrichment research has been undertaken to classify gene sets that vary greatly between BC tissues and normal tissues. Cox models for additive hazards regression were used to classify genes that were strongly linked to overall survival. A subsequent Cox regression multivariate analysis was used to construct a predictive risk parameter model. Kaplan–Meier survival predictions and log-rank validation have been used to verify the value of risk prediction parameters. Seven genes (PGK1, CACNA1H, IL13RA1, SDC1, AK3, NUP43, SDC3) correlated with glycolysis were shown to be strongly linked to overall survival. Depending on the 7-gene-signature, 1222 BC patients were classified into subgroups of high/low-risk. Certain variables have not impaired the prognostic potential of the seven-gene signature. A seven-gene signature correlated with cellular glycolysis was developed to predict the survival of BC patients. The results include insight into cellular glycolysis mechanisms and the detection of patients with poor BC prognosis.

Download Full-text